The Fordham Law professor whose opinion is made a part of the settlement proposal (I first mentioned last week) in Cain v. Hassan, et al., had this to say about what the MRL direct reporting -- to a committee of the Merck board would mean (from page 7 of his opinion, as filed with the court):
. . . .ensure that the most important information is relayed upward without burdening the Comapny wiht excessive bureaucracy. . . .
We will have to see -- if and when approved by the federal District Court in New Jersey -- whether it will be effective in practice, but I am fairly hopeful that it will be a meaningful change, while not slowing the progress of innovation at the company.